Icrucumab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL |
Chemical Data
C H N O Molecular Weight | ||
Icrucumab is an experimental monoclonal antibody designed for the treatment of various types of cancer. It targets the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays a key role in angiogenesis, the process by which tumors develop new blood vessels to sustain their growth.
Mechanism of Action[edit | edit source]
Icrucumab binds to VEGFR-2, inhibiting the receptor's activity. By blocking VEGFR-2, icrucumab prevents the signaling processes essential for the formation of new blood vessels in tumors. This inhibition of angiogenesis is intended to starve the tumor of nutrients and oxygen, thereby inhibiting its growth and potentially leading to tumor shrinkage.
Clinical Trials[edit | edit source]
The development of icrucumab has involved several clinical trials aimed at evaluating its efficacy and safety in treating various cancers. These studies have explored its use as both a single-agent therapy and in combination with other chemotherapy and targeted therapy agents. The outcomes of these trials are crucial for determining the potential of icrucumab as a viable therapeutic option in oncology.
Pharmacokinetics[edit | edit source]
The pharmacokinetic properties of icrucumab, including its absorption, distribution, metabolism, and excretion, are important in understanding its behavior in the human body. These characteristics influence the dosage regimen and administration strategy for the drug.
Safety and Efficacy[edit | edit source]
As with any experimental therapy, the safety and efficacy of icrucumab are of paramount importance. Clinical trials assess these aspects through various endpoints, including tumor response rate, progression-free survival, overall survival, and the incidence of adverse effects.
Future Directions[edit | edit source]
The future development of icrucumab will depend on the results of ongoing and future clinical trials. If successful, it could become a new treatment option for patients with certain types of cancer, potentially improving outcomes and quality of life.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
